Highlights ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
1.98 ^USD	-1.00%		-1.49%	0.00%

05-09	Transcript : ProQR Therapeutics N.V. - Special Call
05-09	ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer? RNA Editing Program Targeting NTCP for Cholestatic Diseases	05-08	CI
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	01-05	CI
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	12-08	MT
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	12-06	CI
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	11-06	MT
ProQR Therapeutics Says Sale of Ophthalmic Assets to Laboratoires Thea Terminated	27/09/23	MT
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V..	26/09/23	CI
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?135 million.	31/07/23	CI
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event	29/03/23	CI
ProQR Therapeutics Wins Hearing on Key Patent for Axiomer	14/03/23	MT
ProQR Therapeutics N.V. Announces Successful Defense of Key Axiomer(R) Patent Protecting Adar-Mediated RNA Editing	14/03/23	CI
Proqr Therapeutics N.V. and Eli Lilly and Company Enters into an Amended and Restated Research and Collaboration Agreement	23/12/22	CI
Eli Lilly Expands Genetic Medicines Partnership with ProQR Therapeutics	22/12/22	MT
Eli Lilly Expands Collaboration With ProQR on Development of New Genetic Medicines	22/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Highlights

Filters